var data={"title":"Talimogene laherparepvec: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Talimogene laherparepvec: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/790909?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=talimogene-laherparepvec-patient-drug-information\" class=\"drug drug_patient\">see &quot;Talimogene laherparepvec: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45649352\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Imlygic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45504063\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Oncolytic Virus</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45513154\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Administer by intralesional injection into cutaneous, subcutaneous, and/or nodal lesions that are visible, palpable, or detectable by ultrasound. It may not be possible to inject all lesions at each treatment visit or over the full course of treatment. Previously injected and/or uninjected lesion(s) may be treated at subsequent visits.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Melanoma, unresectable:</b> Intralesional: Maximum volume (per treatment visit, for all injected lesions combined): 4 mL. Continue treatment for at least 6 months unless other therapy is necessary or until there are no injectable lesions to treat. Reinitiate treatment if new unresectable lesions appear after a previous complete response.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">Use the following to determine the volume of talimogene laherparepvec to be injected (lesion size is based on longest dimension; when lesions are clustered together, inject them as a single lesion):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&bull; If the lesion size is &gt;5 cm, inject up to 4 mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&bull; If the lesion size is &gt;2.5 cm to 5 cm, inject up to 2 mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&bull; If the lesion size is &gt;1.5 cm to 2.5 cm, inject up to 1 mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&bull; If the lesion size is &gt;0.5 cm to 1.5 cm, inject up to 0.5 mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&bull; If the lesion size is &le;0.5 cm, inject up to 0.1 mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">\n      <i>Initial treatment visit:</i> Inject up to 4 mL at a concentration of 10<sup>6</sup> (1 million) PFU/mL. Inject largest lesion(s) first; inject remaining lesion(s) based on lesion size until maximum injection volume is reached or all lesions have been treated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">\n      <i>Second treatment visit (3 weeks after initial treatment):</i> Inject up to 4 mL at a concentration of 10<sup>8</sup> (100 million) PFU/mL. Inject any new lesion(s) that have developed since initial treatment first; inject remaining lesion(s) based on lesion size until maximum injection volume is reached or all lesions have been treated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">\n      <i>All subsequent treatment visits, including reinitiation (2 weeks after previous treatment):</i> Inject up to 4 mL at a concentration of 10<sup>8</sup> (100 million) PFU/mL. Inject any new lesion(s) that have developed since previous treatment first; inject remaining lesion(s) based on lesion size until maximum injection volume is reached or all lesions have been treated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45513155\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45513156\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Dosage adjustment for renal impairment:</b> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45513157\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Dosage adjustment for hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45649353\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. </p>\n    <p style=\"text-indent:0em;\">Suspension, Intralesional [preservative free]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Imlygic: 10<sup>6</sup> (1 million) PFU/mL (1 mL); 10<sup>8</sup> (100 million) PFU/mL  (1 mL) [contains bovine serum]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45525211\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Imlygic: http://pi.amgen.com/united_states/imlygic/imlygic_mg.pdf</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45513159\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer by intralesional injection into cutaneous, subcutaneous, and/or nodal lesions that are visible, palpable, or detectable by ultrasound. Clean the lesion and surrounding areas with alcohol and allow to dry. If necessary, treat the injection site with a topical or local anesthetic agent (but do not inject the anesthetic directly into the lesion [inject around periphery of lesion]). Using a single insertion point, inject talimogene laherparepvec (using a 22 to 26 gauge needle) along multiple tracks as far as the needle allows within the lesion to achieve dispersion; multiple lesion points may be used if a lesion is larger than the radial reach of the needle.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Inject talimogene laherparepvec evenly and completely within the lesion by pulling the needle back without removing it from the lesion. Redirect the needle as necessary while injecting the remainder of the dose; continue until the full dose is evenly and completely dispersed. Remove the needle from the lesion slowly to avoid leakage. Repeat steps for other lesions to be treated. Use a new needle if the needle is completely removed from a lesion and each time a different lesion is injected. Apply pressure with sterile gauze for at least 30 seconds after the injection is completed; swab the injection site(s) and surrounding areas with alcohol. Change gloves, then cover lesion(s) with an absorbent pad and dry occlusive dressing, and wipe the exterior of the dressing with alcohol. The injection site should be covered for at least the first week after each treatment or longer if the injection site is weeping or oozing (replace dressing if it falls off).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Immunocompromised or pregnant health care providers should not prepare or administer talimogene laherparepvec and should not have direct contact with injection sites, dressings, or body fluids of treated patients. Avoid accidental exposure; follow biohazard precautions (personal protective equipment) for administration. Patients should place used dressings and cleaning materials in a sealed plastic bag and dispose of with household waste.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49161145\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (meets NIOSH 2016 criteria). This medication is not on the NIOSH (2016) list; however, it meets the criteria for a hazardous drug. Drugs are classified as hazardous based on their properties; the properties of a hazardous drug include one or more of the following characteristics: carcinogenic, teratogenic (or other developmental toxicity), reproductive toxicity, organotoxic at low doses, genotoxic, and/or new agents with structural or toxicity profiles similar to existing hazardous agents. Assess risk to determine appropriate containment strategy (USP-NF 2017).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, and ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator) for preparation. Double gloving and a protective gown are required during administration (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45503700\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Melanoma, unresectable:</b> Treatment (local) of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limitations of use: Has not been shown to improve overall survival or have an effect on visceral metastases.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45512094\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its lists of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Health care providers who are immunocompromised or pregnant should not prepare or administer talimogene laherparepvec and should not come into direct contact with injection sites, dressings, or body fluids of treated patients.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45511973\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Most reactions resolved within 72 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (50%), chills (49%), headache (19%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (36%), vomiting (21%), diarrhea (19%), constipation (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Pain at injection site (28%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Myalgia (18%), arthralgia (17%), limb pain (16%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Flu-like symptoms (31%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (43%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Weight loss (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain (9%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Oropharyngeal pain (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Deep vein thrombosis, vasculitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Cellulitis, dermatitis, exacerbation of psoriasis, skin rash, vitiligo</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Oral herpes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Bacterial infection (systemic), herpes virus infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Herpes simplex keratitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Glomerulonephritis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Acute asthma, pneumonitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45503701\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Immunocompromised patients, including those with a history of primary or acquired immunodeficient states, leukemia, lymphoma, AIDS or other clinical manifestations of infection with human immunodeficiency viruses, and those on immunosuppressive therapy; pregnancy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45512099\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immune-mediated events: Immune-mediated events (eg, glomerulonephritis, pneumonitis, vasculitis, vitiligo, and worsening psoriasis) have been reported in clinical studies. Consider risk/benefit ratio of initiating treatment in patients with underlying autoimmune disease or prior to continuing talimogene laherparepvec treatment in patients who develop immune-mediated events.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infection: Herpetic infections (eg, cold sores and herpetic keratitis) have been reported; disseminated herpetic infection may occur in immunocompromised patients. If herpes-like lesions develop, follow standard practice to prevent viral transmission; contact a health care provider for evaluation. Suspected herpetic lesions should be reported to Amgen at 1-855-465-9442.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Injection-site complications: Injection-site complications, such as necrosis, tumor tissue ulceration, and impaired healing, may occur during treatment with talimogene laherparepvec. Cellulitis and systemic bacterial infection have been observed. Monitor wounds carefully; infection precautions are recommended, particularly if tissue necrosis results in open wounds. Patients with underlying risk factors for impaired wound healing (eg, previous radiation at the injection site or lesions in poorly vascularized areas) may be at risk for complications. One patient had a lower extremity amputation 6 months after talimogene laherparepvec administration due to an infected non-healing wound. Monitor closely. Consider risk/benefit of continued treatment in patients with persistent infection or impaired wound healing at injection site(s).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary toxicity: Obstructive airway disorder has been observed following talimogene laherparepvec therapy; use caution when injecting lesions close to major airways.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Multiple myeloma: In one clinical study, a patient with smoldering multiple myeloma developed a plasmacytoma near the talimogene laherparepvec injection site. Consider the risks/benefits of talimogene laherparepvec therapy in patients with multiple myeloma or in those who develop plasmacytoma during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acyclovir: Talimogene laherparepvec is sensitive to acyclovir. Acyclovir (or other antiviral medications) may interfere with the efficacy of talimogene laherparepvec; consider the risks and benefits of treatment prior to administering antiviral agents.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dose strength: Talimogene laherparepvec is available in two different dose strengths: 10<sup>6</sup> (1 million) plaque-forming units (PFU) per mL (initial dose only), and 10<sup>8</sup> (100 million) PFU per mL (all subsequent doses). Verify appropriate dose and vial prior to preparation and administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special handling:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hazardous agent: Health care providers who are immunocompromised or pregnant should not prepare or administer talimogene laherparepvec. Accidental talimogene laherparepvec exposure may lead to herpetic infection. Health care providers, close contacts (eg, household members, caregivers, sex partners, or persons sharing the same bed), pregnant women, and newborns should avoid direct contact with injected lesions, dressings, or body fluids of patients treated with talimogene laherparepvec. Protective gloves should be worn when assisting patients with dressing changes; safely dispose of used dressings, gloves, and cleaning materials. Needle stick and/or splashback to the eyes have been reported during talimogene laherparepvec preparation and administration. If accidently exposed to talimogene laherparepvec, clean the affected area thoroughly with soap and water and/or a disinfectant. Contact a health care provider if signs/symptoms of herpetic infection develop. Counsel patients to avoid touching or scratching injection site(s) or the dressings (may lead to inadvertent transfer of drug to other parts of the body).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45525329\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45525326\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=104964&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Antiherpetic Antivirals: May diminish the therapeutic effect of Talimogene Laherparepvec.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45512097\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Use is contraindicated in pregnant women.</p>\n    <p style=\"text-indent:0em;margin-top:0em;\">Women of reproductive potential should use effective contraception during therapy. Talimogene laherparepvec is a live, attenuated, genetically modified herpes simplex virus type 1 (HSV-1). HSV-1 is known to cross the placenta, can be transmitted during birth, and produce infections in the fetus or neonate. It is not known if this can occur following exposure to talimogene laherparepvec. Pregnant women should not prepare or administer this medication. Pregnant women who are in close contact of patients treated with talimogene laherparepvec should not change dressings or clean injection sites, and should avoid direct contact with the injection site, dressings, or body fluids of patients.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45512098\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if talimogene laherparepvec is present in breast milk. The manufacturer recommends a decision be made to discontinue breastfeeding or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45517054\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor for signs/symptoms of herpetic infections (eg, cold sores and herpetic keratitis), injection-site complications, obstructive airway disease, and immune-mediated events</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45513105\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Talimogene laherparepvec is a genetically modified attenuated herpes simplex virus 1 (HSV) oncolytic virus which selectively replicates in and lyses tumor cells (Andtbacka 2015). Talimogene laherparepvec is modified through deletion of two nonessential viral genes. Deletion of the herpes virus neurovirulence factor gene ICP34.5 diminishes viral pathogenicity and increases tumor-selective replication; deletion of the ICP47 gene reduces virally mediated suppression of antigen presentation and increases the expression of the HSV US11 gene (Andtback 2015). Virally derived GM-CSF recruits and activates antigen-presenting cells, leading to an antitumor immune response.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45513107\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Time to peak: Peak levels of talimogene laherparepvec were detected in the urine on the day of treatment</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45762889\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Imlygic Intralesional)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000000 units/mL (1 mL): $57.53</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100000000 units/mL (1 mL): $5,752.81</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49940046\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Imlygic (AT, AU, CZ, DE, DK, EE, GB, HR, IE, LT, LV, NO, PT, SK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. <i>J Clin Oncol</i>. 2015;33(25):2780-2788.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/talimogene-laherparepvec-drug-information/abstract-text/26014293/pubmed\" target=\"_blank\" id=\"26014293\">26014293</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Imlygic (talimogene laherparepvec) [prescribing information]. Thousand Oaks, CA: BioVex, Inc; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 104964 Version 35.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F45649352\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F45504063\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F45513154\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F45513155\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F45513156\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F45513157\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F45649353\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F45525211\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F45513159\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49161145\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F45503700\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F45512094\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F45511973\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F45503701\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F45512099\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F45525329\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F45525326\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F45512097\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F45512098\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F45517054\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F45513105\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F45513107\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F45762889\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F49940046\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/104964|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=talimogene-laherparepvec-patient-drug-information\" class=\"drug drug_patient\">Talimogene laherparepvec: Patient drug information</a></li></ul></div></div>","javascript":null}